Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AlloVir (ALVR)
NASDAQ:ALVR
AlloVir (ALVR) Stock Price & Analysis
341 Followers
ALVR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.62 - $6.12
Previous Close$0.76
Volume534.24K
Average Volume (3M)884.53K
Market Cap
$84.85M
Enterprise Value-$71.67M
Total Cash (Recent Filing)$183.94M
Total Debt (Recent Filing)$27.43M
Price to Earnings (P/E)-0.4
Beta1.40
Next Earnings
May 02, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding114,869,175
10 Day Avg. Volume424,538
30 Day Avg. Volume884,533
Standard Deviation0.24
R-Squared0.03
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.58
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.37
Forecast
1Y Price Target
$1.00Price Target Upside34.75% Upside
Rating ConsensusHold
Number of Analyst Covering1
AlloVir News
PremiumCompany Announcements
AlloVir Faces Delisting Risk, Considers Reverse Split to Comply
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe company's SG&A expenses have been managed effectively, as evidenced by costs coming in below estimates.
Financial StabilityThe company's strong cash position is expected to fund operations well into the future.
Investment In GrowthIncreased R&D spending signals the company's commitment to innovation and future growth.
Bears Say
Clinical SetbacksAlloVir recently announced the discontinuation of multiple Phase 3 studies for posoleucel following an unexpected and disappointing review that recommended all three studies be stopped for futility.
Operational DownsizingThe company has announced a 95% workforce reduction, consistent with plans to explore strategic alternatives and preserve cash.
Strategic UncertaintyALVR has not set a timetable for the completion of its strategic review and the Board of Directors has not approved a definitive course of action.
---
Ownership Overview
Currently, No data available
---
ALVR FAQ
What was AlloVir’s price range in the past 12 months?
AlloVir lowest stock price was $0.62 and its highest was $6.12 in the past 12 months.
What is AlloVir’s market cap?
Currently, no data Available
When is AlloVir’s upcoming earnings report date?
AlloVir’s upcoming earnings report date is May 02, 2024 which is in 13 days.
How were AlloVir’s earnings last quarter?
Currently, no data Available
Is AlloVir overvalued?
According to Wall Street analysts AlloVir’s price is currently Undervalued.
Does AlloVir pay dividends?
AlloVir does not currently pay dividends.
What is AlloVir’s EPS estimate?
AlloVir’s EPS estimate is -$0.16.
How many shares outstanding does AlloVir have?
AlloVir has 114,063,340 shares outstanding.
What happened to AlloVir’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AlloVir?
Among the largest hedge funds holding AlloVir’s share is Woodline Partners LP. It holds AlloVir’s shares valued at 2M.
---
AlloVir Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (34.75% Upside)
$1.00 (34.75% Upside)
Blogger Sentiment
Bullish
ALVR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $78.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.44%
12-Months-Change
Fundamentals
Return on Equity
-102.85%
Trailing 12-Months
Asset Growth
-31.14%
Trailing 12-Months
Company Description
AlloVir
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
---
ALVR Stock 12 Months Forecast
Average Price Target
$1.00
▲(34.75% Upside)
Technical Analysis
Best Analysts Covering ALVR
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-51.19%
downgraded a sell rating 4 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -51.19% per trade.
---